novo nordisk cuts prices for its glp-1 drugs. launches Wegovy weight-loss pill in US, triggering price war | Pharmaceuticals industry Novo Nordisk to slash Wegovy,

Standard Medicare Part D covers Wegovy for cardiovascular risk reduction, Zepbound for moderate-to-severe obstructive sleep apnea, and Wegovy for noncirrhotic MASH with moderate-to-advanced liver fibrosis

Wegovy beat Zepbound to market with FDA approval for obesity, but Zepbounds weekly US prescriptions were nearly double Wegovys last month, per Reuters tracking data

Industry activity suggests rapid development in this area [14], but clinical adoption will depend on functional benefits, safety, cost-effectiveness and regulatory guidance

Eur J Gastroenterol Hepatol 29(12):13851388

[DOI] [PubMed] [Google Scholar] 127.Seino Y, Min KW, Niemoeller E, Takami A

Astrup, A, Carraro, R, Finer, N, et al